EDVANYSEBeveragesFiscal year ends December 31
Endovia Health Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.14−0.01 (-7.53%)
Close on Oct 19, 2026
- Market cap
- $413.76K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$7.1050 (−98.14%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Endovia Health Sciences, Inc. saw revenue fall 90.9% to $73.07K over fiscal 2025.
Revenue
$73.07K
-90.9% vs. a year earlier
Operating income
-$13.51M
TTM Q2 2026
EPS, diluted
-$25.18
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $413.76K
- P/E ratio
- –
- Price to sales
- 5.66
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $73.07K
- Net income
- -$17.28M
- EPS, diluted
- -$25.18
- Book value per share
- -$5.14
- Diluted shares
- 3M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
$25.35K
Operating income
-$13.51M
Net income
-$17.28M
EPS, diluted
-$25.18
Free cash flow
–
Reported periodTrailing twelve months